Telomir Pharmaceuticals

Telomir Pharmaceuticals

Telomir Pharmaceuticals was incorporated in 2021 and maintains its headquarters in Tampa, Florida. The company is led by Chairman and CEO Erez Aminov, who has steered the firm toward a single-axis thesis: intervening in telomere degradation can modulate the aging process and treat chronic, age-associated conditions. The company's lead candidate, Telomir-1, is a small-molecule compound designed to target cellular aging by preserving telomere length. Development strategy concentrates on one initial indication — Osteoarthritis — with preclinical work underway exploring broader applications in progeria, Alzheimer's, and other degenerative diseases. As of mid-2024, Telomir has not filed an Investigational New Drug (IND) application with the FDA; its pipeline remains entirely preclinical, with no partnered or out-licensed assets reported publicly. Telomir operates on a biotech discovery platform model with a lean internal team and no disclosed institutional co-investors. The firm went public in 2024 through a direct listing on the Nasdaq under the ticker 'TELO,' raising capital to fund its preclinical and early clinical development program. There are no disclosed satellite vehicles, foundation structures, or operating-business adjacencies beyond the core pharmaceutical development entity. Telomir's structural distinction is its narrow focus on a single molecular target — telomere length — across multiple disease states, bypassing the standard biotech strategy of diversifying across unrelated biological pathways. This concentration risk is paired with a direct-listing go-public path rather than a traditional venture-capital syndicate, a less common financing architecture for preclinical biotechs.